Abstract
Main purpose
The objective of this study was to determine the relationship between clinician-graded symptoms based on the common toxicity criteria (CTC) and patient-reported quality of life (QoL). We hypothesized that toxicity symptoms that are objective or observable would have a higher correlation with QoL than subjective data.
Material and methods
A retrospective analyses of data from three closed randomized chemotherapy trials was performed. A total of 2,110 patients with ovarian cancer (stage IIB–IV) who had complete toxicity and QoL data at cycles 3 and 6 were included. Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria. Quality of life was assessed every other cycle by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).
Main results
Correlations between CTC grading and the QLQ-C30 functioning scales were weak (<0.30); correlation coefficients between CTC ratings and the QLQ-C30 symptom scales including nausea, vomiting, constipation, pain, and dyspnea ranged from 0.32 to 0.49 except for constipation (0.55). On a symptom level exact agreement between clinician and patient reporting ranged from 54.2% (pain) to 80.8% (emesis/vomiting). When symptom grading differed, patients reported greater severity for pain, constipation, and dyspnea, whereas clinicians graded emesis/vomiting and nausea as more severe than the grading by patients.
Conclusion
Patient experience is not routinely captured by CTC toxicity scales. Therefore, clinicians should not entirely rely on the CTC grading but consider patient-reported outcomes as well.
Similar content being viewed by others
References
National Cancer Institute (1999) Common Toxicity Criteria version 2.o (CTC). http://www.77ctep.cancer.gov/reporing/CTC-3.html
Bentzen SM, Dorr W, Anscher MS et al (2003) Normal tissue effects: reporting and analysis. Semin Radiat Oncol 13:189–202
Trotti A, Colevas AD, Setser A et al (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121–5127
Velikova G, Wright P, Smith AB et al (2001) Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. J Clin Oncol 19:2064–2073
Strömgren AS, Groenvold M, Pedersen L (2002) Symptomatology of cancer patients in palliative care: content validation of self-assessment questionnaires against medical records. Eur J Cancer 38:788–794
Geels P, Eisenhauer E, Bezjak A (2000) Palliative effects of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395–2405
Petersen M, Larsen H, Pedersen L et al (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42:1159–1166
Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinician symptoms reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire based study. Lancet Oncol 7:903–908
Varricchio CG, Sloan JA (2002) The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst 94:1184–1184
Wilson KA, Dowling AJ, Abdolell M et al (2000) Perception of quality of life by patients, partners and treating physicians. Qual Life Res 9:1041–1052
Butler L, Bacon M, Carey M et al (2004) Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 22:2461–2468
Fromme EK, Eilers KM, Mori M et al (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality of life questionnaire C30. J Clin Oncol 22:3485–3490
Huschka MM, Mandrekar SJ, Jett JR et al (2007) A pooled analysis of quality of life measures and adverse events data in North Central Cancer Treatment Group lung cancer clinical trials. Cancer 109:787–795
Basch E, Jia X, Heller G et al (2009) Adverse symptom reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632
U.S. Department of Health and Human Services Food and Drug Administration (2007) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http://www.fda.gov/cder/guidance/5460dft.htm
Aaronson NK, Ahmedzai SM, Bergmann B et al (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376
Huschka M, Burger K (2006) Does QOL provide the same information as toxicity data? Curr Probl Cancer 30:244–254
du Bois A, Lück HJ, Meier W et al (2003) Randomized clinical trial of Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1330
du Bois A, Weber B, Rochon J et al (2006) Addition of Epirubicin as a third drug to Carboplatin-Paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized Gynecologic Cancer Intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and The Groupe d’Investigateurs Nationaux pour L’Etude des Cancers Ovariens. J Clin Oncol 24:1127–1135
Pfisterer J, Weber B, Reuss A et al (2006) Randomized phase III Trial of Topotecan following Carboplatin and Paclitaxel in first-Line treatment of advanced ovarian cancer: a gynecologic Intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98:1036–1045
Fayers P, Aaronson N, Bjordal K et al (2001) EORTC QLQ-C30 scoring manual, 3rd edn. EORTC publications, Brussels
Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawerence Earlbaum Associates, Hillsdale
Greimel E, Bjelic-Radisic V, Pfisterer J et al (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with Cisplatin/Paclitaxel versus Carboplatin/Paclitaxel. J Clin Oncol 24:579–586
Acknowledgments
We thank the following experts for their contribution: K. Baumann, A. Belau, H. Eidtmann, D. Elling, M. Gropp, P. Harter, J. Huober, Keil E, W. Kuhn, S. Loibl, W. Meier, G von Minckwitz, B. Schmalfeldt, J. Sehouli, A. Stähle, M. Untch, and K. Wollschlaeger. We thank all patients, the study office staff, and the statistical department of the AGO for their support. This work was not funded, but the original studies had been supported by Bristol-Myers-Squibb, Pfizer, and Glaxo-Smithkline.
Conflict of interest statement
The authors have no conflict of interest.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Greimel, E.R., Bjelic-Radisic, V., Pfisterer, J. et al. Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer 19, 1421–1427 (2011). https://doi.org/10.1007/s00520-010-0969-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-010-0969-8